Valiant Laboratories Reports Strong Q2 & H1 FY26 Results, Returns to Profitability
Valiant Laboratories reported robust Q2 and H1 FY26 financial results, achieving significant revenue growth and a strong return to profitability both standalone and consolidated, following board approval on November 11, 2025.
The shift from considerable losses to profitability indicates a strong fundamental improvement in the company's performance and financial health, which is a major positive development for investors and stakeholders.
The company demonstrated a significant turnaround, moving from substantial losses in the previous year to net profits for both the quarter and half-year ended September 30, 2025. Revenue also saw strong growth across both standalone and consolidated results.
* Valiant Laboratories Limited's Board of Directors approved the Audited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2025, in a meeting held on November 11, 2025. * Standalone Performance (Q2 FY26 vs Q2 FY25): * Revenue from Operations surged to ₹4,596.77 lakhs from ₹2,147.90 lakhs. * Net Profit for the period was ₹16.67 lakhs, a significant turnaround from a net loss of ₹598.29 lakhs in the prior year. * Basic Earnings Per Share (EPS) improved to ₹0.03 from ₹(1.39). * Standalone Performance (H1 FY26 vs H1 FY25): * Revenue from Operations increased to ₹9,699.49 lakhs from ₹4,036.33 lakhs. * Net Profit for the period was ₹196.24 lakhs, compared to a net loss of ₹698.56 lakhs in the previous half-year. * Basic EPS for the half-year stood at ₹0.36, up from ₹(1.61). * Consolidated Performance (Q2 FY26 vs Q2 FY25): * Revenue from Operations grew to ₹4,620.24 lakhs from ₹2,147.90 lakhs. * Net Profit for the period was ₹20.01 lakhs, a substantial improvement from a net loss of ₹474.08 lakhs in the prior year. * Basic EPS rose to ₹0.04 from ₹(0.33). * Consolidated Performance (H1 FY26 vs H1 FY25): * Revenue from Operations reached ₹9,302.52 lakhs from ₹4,036.33 lakhs. * Net Profit for the period was ₹202.10 lakhs, compared to a net loss of ₹525.01 lakhs in the previous half-year. * Basic EPS for the half-year was ₹0.04, up from ₹(0.33).
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.